Extended Data Fig. 9: FSP1 and GCLC inhibition reduces LN cell viability under 21% and 1% O2.
From: Lymph node environment drives FSP1 targetability in metastasizing melanoma
a, Cell viability of B16-F0 and LN7 1134BL WT and FSP1 KO lines treated with RSL3 under 21% O2 for 48 h. b, Cell viability of B16-F0 WT, B16-F0 FSP1 KO, LN7 1134BL WT, and LN7 1134BL FSP1 KO lines ± RSL3 (0.1 μM and 0.25 μM) under 21% or 1% O2 for 48 h. c, Immunoblot of FSP1 protein levels in LN9 1315BL WT and LN9 1315BL FSP1 KO clones. d, Cell viability of LN9 1315BL WT and FSP1 KO lines treated with RSL3 under 21% O2 for 48 h. e, Cell viability of B16-F0 and LN7 1134BL WT and FSP1 KO lines treated with ML-210 under 1% O2 for 48 h. f, Cell viability assay of B16-F0 WT, B16-F0 FSP1 KO, LN7 1134BL WT, and LN7 1134BL FSP1 KO lines ± ML-210 (2.5 μM) under 1% O2 for 48 h. g, Cell viability of B16-F0 and LN7 1134BL cells ± RSL3 (0.25 μM), viFSP1 (15 μM or 30 μM), or combinations under 21% and 1% O2 for 48 h. h, Cell viability of B16-F0 and LN metastatic lines treated with viFSP1 under 21% O2 for 48 h. i, Cell viability of B16-F0, LN7 1134BL WT and FSP1 KO lines ± BSO (1 mM and 3 mM) under 1% O2 for 48 h. j,k, Cell viability of A-375 cells ± iFSP1 (10 μM) (j) or FSEN1 (10 μM) (k) ± BSO (1 mM) or combinations. n = 3 technical replicates for a, b, d-f, h-k or n = 6 technical replicates for g, representative of 1 of 3 independent experiments. Data in a,b, d-k shown mean ± s.d. Statistical significance was determined using one-way ANOVA followed by Sidak’s multiple comparisons test (b, f, g, i–k).
